Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes
Artavazd Tadevosyan1, Eric J MacLaughlin2, Vardan T Karamyan31Departments of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada; 2Department of Pharmacy Practice, 3Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech Uni...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-01-01
|
| Series: | Patient Related Outcome Measures |
| Online Access: | http://www.dovepress.com/angiotensin-ii-type-1-receptor-antagonists-in-the-treatment-of-hyperte-a6135 |
| _version_ | 1819081752557125632 |
|---|---|
| author | Artavazd Tadevosyan Eric J MacLaughlin Vardan T Karamyan |
| author_facet | Artavazd Tadevosyan Eric J MacLaughlin Vardan T Karamyan |
| author_sort | Artavazd Tadevosyan |
| collection | DOAJ |
| description | Artavazd Tadevosyan1, Eric J MacLaughlin2, Vardan T Karamyan31Departments of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada; 2Department of Pharmacy Practice, 3Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USAAbstract: Hypertension in the elderly is one of the main risk factors of cardiovascular and cerebrovascular diseases. Knowledge regarding the mechanisms of hypertension and specific considerations in managing hypertensive elderly through pharmacological intervention(s) is fundamental to improving clinical outcomes. Recent clinical studies in the elderly have provided evidence that angiotensin II type 1 (AT1) receptor antagonists can improve clinical outcomes to a similar or, in certain populations, an even greater extent than other classical arterial blood pressure-lowering agents. This newer class of antihypertensive agents presents several benefits, including potential for improved adherence, excellent tolerability profile with minimal first-dose hypotension, and a low incidence of adverse effects. Thus, AT1 receptor antagonists represent an appropriate option for many elderly patients with hypertension, type 2 diabetes, heart failure, and/or left ventricular dysfunction.Keywords: angiotensin II, ARB, cardiovascular disease, antihypertensive therapy, elderly |
| first_indexed | 2024-12-21T20:05:46Z |
| format | Article |
| id | doaj.art-8959274f63ae413d98b0a08ce8b8ce08 |
| institution | Directory Open Access Journal |
| issn | 1179-271X |
| language | English |
| last_indexed | 2024-12-21T20:05:46Z |
| publishDate | 2011-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Related Outcome Measures |
| spelling | doaj.art-8959274f63ae413d98b0a08ce8b8ce082022-12-21T18:51:52ZengDove Medical PressPatient Related Outcome Measures1179-271X2011-01-012011default2739Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomesArtavazd TadevosyanEric J MacLaughlinVardan T KaramyanArtavazd Tadevosyan1, Eric J MacLaughlin2, Vardan T Karamyan31Departments of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada; 2Department of Pharmacy Practice, 3Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USAAbstract: Hypertension in the elderly is one of the main risk factors of cardiovascular and cerebrovascular diseases. Knowledge regarding the mechanisms of hypertension and specific considerations in managing hypertensive elderly through pharmacological intervention(s) is fundamental to improving clinical outcomes. Recent clinical studies in the elderly have provided evidence that angiotensin II type 1 (AT1) receptor antagonists can improve clinical outcomes to a similar or, in certain populations, an even greater extent than other classical arterial blood pressure-lowering agents. This newer class of antihypertensive agents presents several benefits, including potential for improved adherence, excellent tolerability profile with minimal first-dose hypotension, and a low incidence of adverse effects. Thus, AT1 receptor antagonists represent an appropriate option for many elderly patients with hypertension, type 2 diabetes, heart failure, and/or left ventricular dysfunction.Keywords: angiotensin II, ARB, cardiovascular disease, antihypertensive therapy, elderlyhttp://www.dovepress.com/angiotensin-ii-type-1-receptor-antagonists-in-the-treatment-of-hyperte-a6135 |
| spellingShingle | Artavazd Tadevosyan Eric J MacLaughlin Vardan T Karamyan Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes Patient Related Outcome Measures |
| title | Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes |
| title_full | Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes |
| title_fullStr | Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes |
| title_full_unstemmed | Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes |
| title_short | Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes |
| title_sort | angiotensin ii type 1 receptor antagonists in the treatment of hypertension in elderly patients focus on patient outcomes |
| url | http://www.dovepress.com/angiotensin-ii-type-1-receptor-antagonists-in-the-treatment-of-hyperte-a6135 |
| work_keys_str_mv | AT artavazdtadevosyan angiotensiniitype1receptorantagonistsinthetreatmentofhypertensioninelderlypatientsfocusonpatientoutcomes AT ericjmaclaughlin angiotensiniitype1receptorantagonistsinthetreatmentofhypertensioninelderlypatientsfocusonpatientoutcomes AT vardantkaramyan angiotensiniitype1receptorantagonistsinthetreatmentofhypertensioninelderlypatientsfocusonpatientoutcomes |